Aptorum: developing novel mechanisms for the treatment of infectious diseases

Aptorum is developing novel drugs that tackle bacteria and viruses. Acting as the commercialization platform in partnership with major academic and research institutions, the company has in-licensed a number of infectious-disease-targeted compounds and methods from Hong Kong academic institutions and through the company’s research and development team continue to advance them toward clinical development. Aptorum is now looking to develop further projects with collaborators globally.

Thumb 00
Jun 10, 2019
1
0
Page of
Medium 00

Aptorum

Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs. Aptorum Group is pursuing therapeutic and diagnostic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas as well as non-therapeutic areas such as surgical robotics and the operations of its medical clinic in Hong Kong, Talem Medical, with the initial focus on treatment of chronic diseases resulting from modern sedentary lifestyles and aging population.

No comments yet.